STOCK TITAN

Coherus Management to Present at Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

REDWOOD CITY, Calif., March 04, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the following investor conferences in March.

  • 42nd Annual Cowen Health Care Conference on Wednesday, March 9 at 10:30 a.m. ET
  • Barclays Global Healthcare Conference on Tuesday, March 15 at 2:35 p.m. ET

Audio webcasts of these presentations will be available on the investors’ page of the Coherus website at http://investors.coherus.com. Please access the website prior to the start of the presentation to ensure a timely connection to the webcast. Each webcast will be archived on the Coherus website for 30 days.

Coherus Contact Information:
IR Contact:
McDavid Stilwell
Coherus BioSciences, Inc.
IR@coherus.com


Coherus BioSciences, Inc.

NASDAQ:CHRS

CHRS Rankings

CHRS Latest News

CHRS Stock Data

233.81M
103.90M
1.35%
77.99%
20.8%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
REDWOOD CITY

About CHRS

coherus biosciences is the leading biologics platform company solely focused on delivering high-quality biosimilar therapeutics that will expand patient access to life-changing medicines in regulated markets worldwide. founded in 2010, coherus is a late-stage biologics platform company focused on the global biosimilar market. headquartered in the san francisco bay area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team's collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. our commercialization partnerships include global pharmaceutical companies in europe, asia and latin america. biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and exp